At ASCO 2026, izalontamab brengitecan became the first bispecific antibody-drug conjugate to improve both progression-free and overall survival in triple-negative breast cancer. Inside the EGFRxHER3 mechanism, the Phase 3 trial…
A new class of AI foundation models trained on millions of whole slide images is reshaping how cancer is diagnosed. Inside Virchow 2, Prov-GigaPath, CHIEF, and the FDA clearance of…
More than thirty targeted protein degraders are now in human trials, with the first Phase 3 readouts arriving in 2026. Inside the vepdegestrant breast cancer data, the BTK degrader race,…
A landmark Science study from Israel’s Weizmann Institute reveals that genetics accounts for roughly 50% of variation in human lifespan, more than double previous estimates, upending decades of thinking about…
An estimated 1.4 billion people carry genetically elevated lipoprotein(a), a cholesterol-like particle that drives premature heart attacks, strokes, and aortic stenosis. For 60 years cardiologists could measure it but not…
A new Atlas of the rarest humans on Earth, the supercentenarians who lived past 110, is rewriting what science thought it knew about aging. Inside George Church’s four-front war on…
GUARDIAN, BEACONS, BabySeq2, BeginNGS, and the NHS Generation Study are running in parallel in 2026. Inside the 12-fold detection signal from Columbia, the $14.4 million NIH multi-state pilot, and what…
A casual conversation between two Mayo Clinic graduate students sparked a discovery that could solve one of longevity medicine’s most stubborn problems: finding the cells that silently drive aging, cancer,…
For two decades after the Human Genome Project, the promise of personalized medicine outran the data. In 2026, that gap is finally closing. Polygenic risk scores built from millions of…
A convergence of preclinical and clinical evidence — from a landmark Cell Metabolism mouse study to the first human epigenetic clock trial — is building the case that GLP-1 receptor…
Zach RobertsSign up for personalized wellness coaching and the Daily Discovery Newsletter.